We can’t show the full text here under this license. Use the link below to read it at the source.
A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD
Comparing combined GLP-1 and SGLT2 treatments to SGLT2 alone in patients with fatty liver disease
AI simplified
Abstract
Combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors is associated with a lower risk of all-cause hospitalization, mortality, and adverse events for metabolic dysfunction-associated steatotic liver disease.
- The primary composite outcomes showed a hazard ratio of 0.87 for combination therapy compared to alone.
- Combination therapy resulted in a 14% reduced risk of all-cause hospitalization (HR, 0.86).
- All-cause mortality risk was significantly lower with combination therapy, yielding a hazard ratio of 0.45.
- The risk of major adverse kidney events was reduced with combination therapy (HR, 0.72).
- Major adverse liver outcomes also showed a reduced risk with combination therapy (HR, 0.61).
- No additional benefits were observed from combination therapy compared to monotherapy, except for all-cause mortality.
AI simplified
Key numbers
0.87
Decrease in Primary Composite Outcome Risk
Hazard Ratio for combination therapy vs. monotherapy
0.45
Decrease in All-Cause Mortality Risk
Hazard Ratio for all-cause mortality with combination therapy vs. monotherapy
0.86
Reduction in All-Cause Hospitalization Risk
Hazard Ratio for all-cause hospitalization with combination therapy vs. monotherapy